The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line, J R Soc Med, vol.99, issue.10, p.17021304, 2006. ,
Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation, Br Med J, vol.2, issue.4582, p.18890300, 1948. ,
A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council, Q J Med, vol.23, issue.91, p.13194851, 1954. ,
A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis, N Engl J Med, vol.371, issue.17, pp.1588-98, 2014. ,
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis, N Engl J Med, vol.371, issue.17, p.4233406, 2014. ,
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis, N Engl J Med, vol.371, issue.17, pp.1577-87, 2014. ,
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion, Am J Respir Crit Care Med, vol.180, issue.6, pp.558-63, 2009. ,
, , p.2742745
Time to publication for results of clinical trials, Cochrane Database Syst Rev, issue.2, p.17443632, 2007. ,
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis, Lancet Respir Med, vol.5, issue.4, 2017. ,
diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study, Lancet, vol.377, issue.9776, p.3085933, 2011. ,
Rapid molecular screening for multidrugresistant tuberculosis in a high-volume public health laboratory in South Africa, Am J Respir Crit Care Med, vol.177, issue.7, p.18202343, 2008. ,
, World Health Organization, Foundation for Innovative New Diagnostics. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2018.
Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis, Am J Respir Crit Care Med, vol.182, issue.5, p.20442432, 2010. ,
Bedaquiline-and delamanid-containing regimens achieve excellent interim treatment response without safety concerns: endTB interim analysis, 2018. ,
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study, Lancet Respir Med, vol.6, issue.9, p.30001994, 2018. ,
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients, Int J Tuberc Lung Dis, vol.18, issue.10, p.25216831, 2014. ,
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future, J Infect Dis, vol.205, issue.2, pp.241-250, 2012. ,
Transmission of Extensively DrugResistant Tuberculosis in South Africa, N Engl J Med, vol.376, issue.3, p.5330208, 2017. ,
The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains, Int J Infect Dis, vol.56, p.28163165, 2017. ,
, Geneva: World Health Organization, 2018.
, Report on Tuberculosis Research Funding Trends, 2005.
Advances in clinical trial design for development of new TB treatments: A call for innovation, PLoS Med, vol.2019, issue.3, p.1002769,
URL : https://hal.archives-ouvertes.fr/inserm-02170758
, Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. Choice of control group and related issues in clinical trials (E10), 2000.
Equipoise and the ethics of clinical research, N Engl J Med, vol.317, issue.3, p.3600702, 1987. ,
, Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update): World Health Organization, 2017.
, World Health Organization. WHO treatment guidelines for multidrug-and rifampicin-resistant tuberculosis, 2018 update. Geneva: World Health Organization, 2018.
Seven myths of randomisation in clinical trials, Stat Med, vol.32, issue.9, p.23255195, 2013. ,
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis, N Engl J Med, vol.366, issue.23, p.22670901, 2012. ,
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrugresistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial, Lancet Respir Med. 2019. Epub, issue.18, pp.30426-30426, 2019. ,
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance, Antimicrob Agents Chemother, vol.56, issue.6, p.22391540, 2012. ,
, , p.3370813
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis, N Engl J Med, vol.360, issue.23, p.19494215, 2009. ,
An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial, Trials, vol.18, issue.1, p.5702225, 2017. ,
Evaluating Ebola therapies-the case for RCTs, N Engl J Med, vol.371, issue.25, pp.2350-2351, 2014. ,
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial, Trials, vol.15, issue.1, p.4164715, 2014. ,
A Bayesian response-adaptive trial in tuberculosis: The endTB trial, Clin Trials, vol.14, issue.1, pp.17-28, 2017. ,
Stream Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials, Eur Respir Rev, vol.25, issue.139, pp.29-35, 2016. ,
Reversals of established medical practices: evidence to abandon ship, JAMA, vol.307, issue.1, p.22215160, 2012. ,
How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know, Clinical Trials, p.1740774518764449, 2018. ,
, World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update: World Health Organization, 2011.
Multidrug-resistant tuberculosis and culture conversion with bedaquiline, N Engl J Med, vol.371, issue.8, pp.723-755, 2014. ,
, Guidance for Industry. Non-inferiority clinical trials to establish effectiveness: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2016.
Shortening treatment of tuberculosis: lessons from fluoroquinolone trials, Lancet Infect Dis, vol.15, issue.2, pp.141-144, 2015. ,
Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review, PLoS ONE, vol.6, issue.4, p.3070694, 2011. ,
Risk-Benefit Analyses Using Novel Methods in the A5279 Latent-TB Clinical Trial. The 49th Union World Conference on Lung Health, 2018. ,
Design issues in pivotal drug trials for drug sensitive tuberculosis (TB), Tuberculosis, vol.88, p.18762156, 2008. ,
Current issues in non-inferiority trials, Stat Med, vol.27, issue.3, p.17340597, 2008. ,
, Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. Statistical Principles for Clinical Trials (E9), 1998.
Challenges in the Design and Interpretation of Noninferiority Trials, N Engl J Med, vol.377, issue.14, pp.1357-67, 2017. ,
, Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. Estimands and sensitivity analysis in clinical trials. E9(R1), 2017.
Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With HypoxicIschemic Encephalopathy: A Randomized Clinical Trial, JAMA, vol.318, issue.16, p.5783566, 2017. ,
, Guidance for Industry. Adaptive designs for clinical trials of drugs and biologics (Draft guidance): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2018.
Innovative trial designs are practical solutions for improving the treatment of tuberculosis, J Infect Dis, vol.205, issue.2, 2012. ,
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis, vol.17, p.28100438, 2017. ,
Unbiased estimation of selected treatment means in two-stage trials, Biom J, vol.50, issue.4, p.18663760, 2008. ,
A review of phase II trial designs for initial marker validation, Clin Trials, vol.36, issue.2, p.23665336, 2013. ,
, , p.3779487
Statistical and practical considerations for clinical evaluation of predictive biomarkers, J Natl Cancer Inst, vol.105, issue.22, p.3888208, 2013. ,
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges, J Clin Oncol, vol.27, issue.24, p.2734400, 2009. ,
Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy, Bull Int Union Tuberc, vol.53, issue.4, p.387141, 1978. ,
Whither short-course chemotherapy?, Br J Dis Chest, vol.75, issue.4, p.7030377, 1981. ,
Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis, Int J Tuberc Lung Dis, vol.20, issue.11, p.27776595, 2016. ,
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis, Nat Med, vol.24, issue.11, p.30397355, 2018. ,
A stratified approach to tuberculosis treatment, Nat Med, vol.24, issue.11, p.30401868, 2018. ,
The CURE-TB Strategy Trial concept on stratified medicine trials in active TB, 2018. ,
Precision medicine needs randomized clinical trials, Nat Rev Clin Oncol, vol.14, issue.5, p.28169302, 2017. ,
Pragmatic Trials, N Engl J Med, vol.375, issue.5, pp.454-63, 2016. ,
What are pragmatic trials?, BMJ, vol.316, issue.7127, p.2665488, 1998. ,
The PRECIS-2 tool: designing trials that are fit for purpose, BMJ, vol.350, p.25956159, 2015. ,
, The use of bedaquiline in the treatment of multidrug-resistant tuberculosis -Interim policy guidance. Geneva: World Health Organization, 2013.
, Rapid Communication: Key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB): World Health Organization, 2018.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, N Engl J Med, vol.373, issue.9, p.4569751, 2015. ,
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF, Lancet Glob Health, vol.3, issue.8, p.26187490, 2015. ,
Building clinical trials capacity for tuberculosis drugs in high-burden countries, PLoS Med, vol.4, issue.11, p.2062480, 2007. ,
New approaches to filling the gap in tuberculosis drug discovery, PLoS Med, vol.4, issue.11, p.2062479, 2007. ,
Randomized trials to optimize treatment of multidrug-resistant tuberculosis, PLoS Med, vol.4, issue.11, p.2062482, 2007. ,
Improving treatment outcomes for MDR-TB-novel host-directed therapies and personalised medicine of the future, Int J Infect Dis, vol.2019, p.30685590 ,